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Abstract
Background—Selenium is an essential trace element which has been implicated in cancer risk;
however, study results have been inconsistent with regard to colon cancer. Our objectives were to 1)
investigate the association between selenium and colon cancer 2) evaluate possible effect measure
modifiers and 3) evaluate potential biases associated with the use of post-diagnostic serum selenium
measures
Methods—The North Carolina Colon Cancer Study is a large population-based, case-control study
of colon cancer in North Carolina between 1996 and 2000 (n=1,691). Nurses interviewed patients
about diet and lifestyle and drew blood specimens which were used to measure serum selenium.
Results—Individuals who had both high serum selenium (>140 mcg/L) and high reported folate
(>354 mcg/day), had a reduced relative risk of colon cancer (OR=0.5, 95% CI=0.4,0.8). The risk of
colon cancer for those with high selenium and low folate was approximately equal to the risk among
those with low selenium and low folate (OR=1.1, 95% CI=0.7,1.5) as was the risk for those with low
selenium and high folate (OR=0.9, 95% CI=0.7–1.2). We did not find evidence of bias due to weight
loss, stage at diagnosis, or time from diagnosis to selenium measurement.
Conclusion—High levels of serum selenium and reported folate jointly were associated with a
substantially reduced risk of colon cancer. Folate status should be taken into account when evaluating
the relation between selenium and colon cancer in future studies. Importantly, weight loss, stage at
diagnosis, or time from diagnosis to blood draw did not appear to produce strong bias in our study.
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Introduction
Worldwide, there is a 25-fold variation in colorectal cancer incidence. The highest rates are
seen in North America, Australia, New Zealand, Western Europe, and select areas of Eastern
Europe.1 Variations in incidence of colorectal cancer with respect to geography and migration
suggest that diet may play an important role in colon cancer etiology.2–4 Selenium is one dietary
factor that could impact colon cancer risk.
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Selenium is an essential trace element found primarily in cereals, wheat, dairy products, meat
and fish. The recommended daily allowance (RDA) of selenium is 55 mcg/day for women and
70 mcg/day for men.5 The tolerable upper limit is 400 mcg/day and deficiency is defined as
less than 30 mcg/day.5 In the United States, plasma selenium levels generally range from 80–
250 mcg/L6, with an average consumption of 125 mcg/day.7 Selenium interacts with a number
of nutrients and micronutrients in the body. Antioxidant nutrients, such as vitamins A, C, E
and zinc enhance selenium absorption.5 Lead, iron, arsenic, copper and methionine also affect
the bioavailability of selenium.5;8–10 More recently, a potential relationship between selenium
and folate has also been suggested.11;12
Selenium is involved in many biochemical pathways, can exist in multiple forms, and can
create a number of different metabolites. Proposed anti-carcinogenic pathways of selenium,
include the repair and prevention of oxidative damage, alteration of metabolism of carcinogenic
agents, regulation of immune response, and P53-independent apoptosis, and repair of DNA
damage.13–16 It is likely that selenium acts as an anti-carcinogen through several mechanisms,
which vary in importance based on disease status of the individual.
Perhaps the most compelling evidence of a relationship between selenium and colon cancer
was provided by the Nutritional Prevention of Cancer Trial (NPC Trial).17 The NPC Trial
(n=1,312) recruited patients with a history of skin cancer from seven dermatology clinics in
the eastern US and randomized them to 200 mcg of selenium (selenized yeast) or placebo per
day. Although there was an increase in incidence of the primary outcome (basal or squamous
cell carcinomas of the skin) over 5 years of follow-up, there was a substantial reduction in
incidence of several other cancers, including colorectal cancer (HR=0.42, 95% CI=0.18–0.95).
After 3 additional years of follow-up, the association between selenium and colorectal cancer
was only slightly attenuated (HR=0.46, 95% CI 0.21–1.02).18
Unlike consumption of most other nutrients, selenium intake is not reliably assessed using self-
report tools, such as food frequency questionnaires, because of the wide variations in soil
selenium. Specifically, the selenium content of plants varies not only with selenium content of
the soil, but with soil pH and moisture and with the type of plant accumulating it.19–21 Meats
are similarly affected because animals grazing on plants in low selenium areas, for instance,
have lower selenium in their meat than animals feeding on plants grown in selenium adequate
or seleniferous areas. Consequently, researchers use biological markers such as serum, plasma,
whole blood, and toenail measures to estimate individual selenium intake in epidemiologic
studies.
A number of studies have reported lower mean selenium levels in colorectal cancer cases than
in controls22–27; however, observational studies providing estimates of the association between
selenium and colon cancer generated inconclusive and inconsistent results. Results are equally
inconsistent in studies using pre- or peri-diagnostic serum (OR range: 0.5–1.7) 23;28–30
compared to those utilizing toenails (OR range: 0.4–2.0).24;31–33 Reasons for these
inconsistent findings are unclear; however, many had small sample sizes, narrow ranges of
exposure, and different ranges of exposure.
Rare diseases such as cancers are often studied using case-control designs. Colon cancer studies
that have biological samples are likely to have post-diagnostic specimens. Factors that may
contribute to bias in the study of post-diagnostic serum selenium and colon cancer are stage at
diagnosis, recent weight loss, time from symptoms to diagnosis, and time from diagnosis to
blood draw. Although these factors have been reported as reasons against using post-diagnostic
serum, there is little empirical support for these concerns.
It has been hypothesized that selenium drops in response to the disease process, either through
changes in nutrition or different metabolic needs of the body.30;34 Individuals with more
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advanced disease are more likely to have lost weight, changed their eating habits, or been
treated with chemotherapy before their blood draw.22;35 If these factors decrease serum
selenium levels, a spurious association between selenium and cancer would be found in patients
with advanced stage disease; results from studies using peri-diagnostic measures would be
biased away from the null. There are limited published information on associations of selenium
and specific colon cancer stages. Weight loss is also of potential importance because decreased
energy intake or possible disease-related metabolic changes resulting in weight loss could lead
to lower selenium levels.36 Weight loss is a common symptom of colorectal cancer and, thus,
an important factor to take into account.37;38 If weight loss does impact selenium levels, use
of post-diagnostic selenium close to diagnosis and treatment could bias the association between
selenium and colon cancer away from the null.
Time from diagnosis to blood draw and time from symptoms to blood draw could be important
in understanding whether selenium responds to disease progression or symptoms of disease
progression. Blood taken very close to the time of diagnosis, potentially in the midst of
chemotherapy, would contribute the most bias if the disease process, treatment, or symptoms
of treatment had an effect on selenium levels. It is possible that symptoms and disease could
have further progressed in those who participated in interviews beyond a year after diagnosis,
making this group subject to biased selenium measurement, as well. It is not likely, however,
that participants who were getting progressively worse over a year or more would have
participated in this study.
The objectives of this study were three-fold. First, we aimed to describe the association between
serum selenium and colon cancer in an effort to provide evidence for or against the further
examination of selenium as a chemopreventive agent for colorectal cancer. As a part of this
objective we used the results of the Nutritional Prevention of Cancer selenium supplementation
trial to inform our definition of high serum selenium to assess a possible “supranutritional
effect” of selenium. Second, we examined possible effect measure modifiers of the association
between selenium and colon cancer. The third objective was to evaluate the validity of using
post-diagnostic measures of selenium in the study of selenium and colon cancer. As part of
this objective, particular attention was given to possible exposure misclassification bias of
selenium due to stage at diagnosis, weight loss, time from symptoms to blood draw, and time
from diagnosis to blood draw
Methods
The North Carolina Colon Cancer Study (NCCCS) is a population-based, case-control study
of colon cancer in North Carolina.39–41 The study area included 33 counties in central North
Carolina representing a socio-economically diverse group of African Americans and
Caucasians. Participants were offered an incentive of $25 for participation in the study. This
study was approved by the Institutional Review Board of the UNC School of Medicine.
Cases were identified through the rapid ascertainment system established in conjunction with
the North Carolina Cancer Registry42 and were eligible for the study if they received a primary
diagnosis of invasive adenocarcinoma of the colon (ICD-9 153) between October 1, 1996 and
October 1, 2000. Other eligibility criteria were as follows: age of 40–80 years at the time of
diagnosis, residence in one of the 33 counties included in the study area, ability to provide
informed consent and to complete an interview, possession of a NC drivers license card or
identification card, and permission to contact primary care physician. Written consent to
examine tissue and medical records was obtained from participants. The study pathologist
confirmed diagnosis and cancer stage through review of pathology slides and pathology
reports.
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Controls were selected from the same 33-county area in central North Carolina as the cases
through a randomized recruitment technique.43 Race-, gender- and age-specific incidence rates
between 1991 and 1993 were used to calculate selection probabilities that would result in
approximately equal numbers of African-American and Caucasian cases. Using these
probabilities, the control group was approximately frequency matched to cases by race, gender,
and age (± 5 yr). Controls were selected from two computerized databases: the North Carolina
Division of Motor Vehicles for persons younger than 65 years and the Health Care Financing
Administration database for those 65 years or older.
There were 1691 completed interviews: 731 African Americans (294 cases; 437 controls) and
957 Caucasians (349 cases; 611 controls). The study cooperation rate [interviewed/
(interviewed + refused)] was 84% for cases and 63% for controls. Cooperation rates were
slightly higher for Caucasians (cases 89%; controls 64%) in comparison to African Americans
(cases 79%; controls 61%).
Data Collection
Data were collected in person by trained nurse interviewers, usually in the participant’s home.
For cases, the median interview time was 5.5 months after diagnosis (range: 1–18 months).
The reference period for the interviews was the year prior to diagnosis (cases) or interview
date (controls). Lifestyle questionnaires were used to gather information on various health-
related behaviors such as smoking, physical activity, and medication use, as well as medical,
family, and employment history.
Diet—Dietary information was obtained using the 100-item semi-quantitative Block food
frequency questionnaire (FFQ) developed at the National Cancer Institute.44 The food
frequency questionnaire was modified by adding 29 foods commonly consumed in North
Carolina in order to better assess regional dietary practices in a sample including African
Americans.45 Controls estimated their usual frequency and serving size during the past year,
whereas cases estimated consumption during the year before diagnosis. A one-year period was
chosen to provide a full cycle of seasons, so that responses would be independent of the time
of year. In a preliminary analysis, we examined the association between selenium and a number
of dietary variables available from the FFQ, including alcohol use, total energy, fat, protein,
beta carotene (vitamin A), vitamin C, vitamin E, zinc, folate, iron, fiber, supplement use
(selenium and multivitamin), red meat, and daily vegetable intake. Dietary risk factors of
interest in multivariate analyses (identified as potential confounders by association with both
selenium and colon cancer in preliminary bivariate analyses) were total energy, total fat, total
folate, total vitamin E, total calcium, total fiber, and red meat consumption. Dietary and
supplemental sources were summed to create total folate, total vitamin E, total calcium and
total fiber values.
Selenium—Serum selenium levels were determined using graphite furnace atomic absorption
spectrometry (GFAAS) with Zeeman background correction and platform technique. GFAAS
uses the characteristic wavelength absorbed from ground-state atoms of an analyte to determine
trace metal concentrations. Serum was mixed with 0.1% Triton X-100 first and then injected
directly into the graphite furnace with the chemical modifier. The concentrations were
calculated using a calibration curve based on aqueous standards. This test can detect levels of
selenium from 2–600 mcg/L.46
Archived serum samples were thawed and aliquotted (100 mcL) into trace-element free vials
for analysis. Samples were mailed in batches of 500 to the laboratory of National Medical
Services (Willow Grove, PA) over a period of several months. All batches contained ten percent
blind controls for external verification of the lab’s coefficient of variation (7%).
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Demographic and lifestyle characteristics—Demographic and lifestyle characteristics
were obtained from the main study questionnaire. A number of demographic and lifestyle
factors were evaluated including age, gender, race, education, smoking, BMI one year before
interview, physical activity, non steroidal inflammatory use (NSAID use) during the past five
years, and first degree family history of colon cancer.
Physical activity (METS/week) was evaluated using a modified version of the seven-day
activity recall used in the Stanford Five-City Project as described in detail elsewhere.47 The
modified version includes five questions on occupational activity. Participants were asked
about work and leisure activity, as well as weekday and weekend activity. Activities were
classified by their energy requirements expressed as metabolic equivalents (METs): very light
(1 MET), light (1.5 METs), moderate (4 METs), hard (7 METs) and very hard (10 METs)
activity. One MET is the amount of energy expended by a 60 Kg person at rest. MET-minutes
per day were calculated by multiplying the METs for each activity by the amount of time spent
in that activity daily.
Weight change was not directly measured in the main questionnaire; it was defined as usual
weight one year prior to interview (self-report) minus weight at time of interview (measured
by interviewer). Time from symptoms to diagnosis and time from diagnosis to blood draw
were also obtained from the main interview questionnaire.
Statistical Analysis
Participants were excluded from the analyses if they had out of range or missing energy
information (n=47), had BMI greater than 50 kg/m2 (n=13), or were of races other than African-
American or Caucasian (n=8). Additionally, eligible subjects who did not give blood or for
whom blood was not available were also excluded from analyses (n=283). One participant with
a selenium value above 300 mcg/L was also deleted from the analysis. Analyses of selenium
and colon cancer included 1,364 participants.
Multivariate logistic regression models were used to describe the relation between selenium
and the presence of colorectal cancer. Selenium was categorized in two ways: dichotomously
(with “high selenium” defined as ≥140 mcg/L) and in fifths (70–105, 106–116, 117–128, 129–
146, 147–290 mcg/L). The value of 140 mcg/L is one standard deviation below the mean in a
group whose selenium intakes were supplemented by 200 mcg/day in the NPC Trial.17 This
specification was used to estimate the possible beneficial effect of selenium supplementation.
Multivariate logistic regression models assessed the relation between high selenium (>=140
mcg/L; highest fifth of selenium) and colon cancer. Known and suspected risk factors for colon
cancer that were measured in the NCCCS were evaluated as potential confounders. Potential
confounders assessed were education (less than high school, high school graduate or some
college, college graduate or more), smoking (current, former, never), alcohol use (none, upper
50%, lower 50%) body mass index (BMI) one year before interview(<18.5, 18.5–25, >25 kg/
m2), physical activity (fifths of metabolic equivalents per day (METs)), non-steroidal
inflammatory (NSAID) use during the past five years (regular, occasional, never), and first
degree family history of colon cancer (yes, no), total energy (<1000, 1000–1500, >1500–2000,
>2000 kilocalories per day), total fat (fifths), total folate (fifths), total vitamin E (fifths), total
calcium (fifths), total fiber (fifths), and red meat (none, <1, >1 serving/day).
Modeling was done by backwards elimination, based on the likelihood ratio test for effect
measure modifiers (α = 0.20) and absolute change in lnOR for confounders (>15%).48 All
potential confounders were assessed as potential effect measure modifiers on both
multiplicative (likelihood ratio test, ratio of relative risks) and additive (interaction contrast
ratio) scales.49 Joint effects of dietary risk factors for colon cancer and selenium were of
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particular interest because they have not been reported in previous studies of selenium and
colon cancer. Multiple logistic models were similarly used to assess the relation between serum
selenium and 1) local colon cancer compared to controls and 2) regional or distant cancer
compared to controls. These analyses were designed to examine whether the relationship
between selenium and colon cancer was restricted to later stage diagnoses. All models were
adjusted for recruitment factors (age, race, and gender) and the offset terms used to identify
eligible participants. The offset term is the value for each age-gender-race stratum calculated
from the selection probabilities used to identify eligible control participants [offset=ln
[probability of case selection/probability of control selection].50
Mean selenium was compared among cases according to several factors thought to affect
selenium levels: stage at diagnosis, time from symptoms to blood draw, time from diagnosis
to blood draw, and weight change in the year before interview. We conducted a simple
sensitivity analysis of the impact of weight loss on the relationship between selenium and local
and regional/distant colon cancer by limiting the study population to cases and controls who
did not experience any weight loss in the year before interview.
We used time from diagnosis to blood draw in order to evaluate whether post diagnosis
selenium levels might result in bias. We reasoned that selenium levels drawn near the time of
diagnosis could be influenced by disease factors (such as weight loss) or treatment factors (such
as surgery or chemotherapy). Therefore, we evaluated whether the same results would have
been achieved if we excluded cases who had their blood drawn shortly after diagnosis (<3
months).
Results
Approximately 85 percent of the total study population had serum selenium measurements
available. Demographic, lifestyle, and dietary characteristics of the study subpopulation with
measured selenium (n=1364) were very similar to the total study population (n=1627) (Table
1), suggesting minimal concern for selection bias from included covariates. Serum selenium
among controls had an approximately normal distribution with a mean of 130 and a range of
71–272 mcg/L of serum. As shown in Table 1, mean selenium was slightly higher among
Caucasian controls (μ=133 mcg/L) in comparison to the African-American controls (μ=125
mcg/L). A large number of dietary factors were also related to selenium status among controls.
Selenium increased with higher reported intakes of vitamin C, vitamin E, zinc, folate, iron,
calcium, fiber, and red meat. As expected, selenium was higher among participants taking
selenium supplements (μ=150 mcg/L) compared to those who were not (μ=130 mcg/L).
Interestingly, selenium was higher in controls who consumed alcohol (μ=138 mcg/L) in
comparison to those who did not (μ=127 mcg/L).
The relation between selenium and characteristics associated with cancer diagnosis and
prognosis among cases was also evaluated (data not shown). Among all colon cancer cases
combined, stage and amount of weight loss were inversely related to selenium (multiple linear
regression coefficient: b= −4.9 (p=0.02) and b= −0.2 (p=0.02), respectively). As the amount
of weight loss increased, selenium decreased; the lowest selenium value by weight change was
in the group that lost over 25 pounds in the year before the interview. Selenium decreased with
advanced disease; the lowest selenium value by stage was seen in distant stage cases.
Time from diagnosis to blood draw did not have a linear relation with selenium(b=0.01
(p=0.14)); however, selenium was lower in those who had their blood taken shortly after
diagnosis (within 3 months). Selenium values were relatively similar amongst those who had
their blood taken ≥3 months after diagnosis. When cases were categorized by stage at diagnosis,
weight change was much more strongly associated with selenium in those with regional or
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distant cancer. Also of interest is that mean weight loss differed by stage (local=−5 lbs.,
regional=−9 lbs., distant=−17 lbs.) and by time from diagnosis to blood draw (<3 months=−15
lbs., 3–6 months=−11 lbs., 6–12 months=−7 lbs., >12 months=0.1 lbs.).
Table 2a shows results from logistic regression models examining associations of all colon
cancers, local colon cancers, and regional or distant colon cancers. All models were adjusted
for age, race, gender and the offset term. Gender, often suspected as an effect measure modifier,
did not modifty the association between selenium and colon cancer on the multiplicative or
additive scales in any of the three models (data not shown). Among the multiple dietary factors
considered, folate (reported through the FFQ) was the only effect measure modifier. In fact,
folate was an effect measure modifier on both scales. To ease interpretation and presentation
of effect measure modification estimates, folate was dichotomized (below and above the
median value among controls; low=<354 mcg/day, high=≥354 mcg/day) in all logistic
regression result tables.
Participants who had high selenium (≥140 mcg/L), without taking reported folate status into
account, were less likely to have colon cancer than those who had low or average selenium
(OR=0.8, 95% CI=0.6,1.0) (data not shown). The joint effects of serum selenium and reported
folate, however, appeared synergistic. A single referent group was used to describe the joint
effects of selenium and folate. Individuals who had both high selenium (>140 mcg/L) and high
folate (≥354 mcg/day) were half as likely to have colon cancer in comparison to individuals
who had low folate and low selenium. The relative risk of colon cancer for those with high
selenium and low folate was essentially null as was the relative risk of colon cancer for those
with low selenium and high folate. Results were similar regardless of stage at diagnosis;
however, evidence of interaction was not as strong in regional/distant cases in comparison to
local cases, as evidenced by the ICR and RRR ranges.
Analyses of selenium in fifths illustrated that among participants with high folate, the strongest
estimated effect was in the upper three fifths of selenium in comparison to the lowest fifth
(Table 2a). There was not a strict monotonic intake-response relationship between selenium
and colon cancer risk. Of note, folate status was not as influential in the association between
selenium and regional or distant colon cancer cases as it was for selenium and local colon
cancer cases.
To assess misclassification of selenium exposure by weight loss, we restricted the analysis to
participants who did not lose weight in the year before their interview (Table 2b). Exclusion
of participants who lost weight in the year before the interview did not appreciably alter our
results. Individuals with high selenium and high folate were less than half as likely to have
colon cancer as those who had low selenium and low folate. This association was similar in
local and regional/distant cancers when selenium and folate were evaluated as dichotomous
variables.
To assess misclassification of selenium exposure by time from diagnosis to blood draw, we
excluded participants who had their blood taken less than 3 months after diagnosis (Table 2c).
Among participants who had their blood taken 3 months or more after diagnosis and treatment,
those with high selenium and high folate were less likely to have colon cancer. The magnitude
of the effect was similar but slightly greater in those with local cancer in comparison to those
with regional or distant cancer.
Discussion
In this study we investigated the relation between selenium and colon cancer while evaluating
several potential sources of bias. The risk of colon cancer for those with high serum selenium
and low reported folate was approximately equal to the risk among those with low selenium
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and low folate as was the risk of colon cancer for those with low selenium and high folate.
However, individuals who had both high selenium and high folate were half as likely to have
colon cancer in comparison to individuals who had low folate and low selenium. When cases
were categorized by stage, results were similar; however, evidence of a synergistic relation
between selenium and folate was slightly stronger in local cases than among regional/distant
cases. We did not find evidence of bias in the association between post diagnostic serum
selenium and colon cancer due to weight loss, stage at diagnosis, or time from diagnosis to
blood draw (selenium measurement).
Our relative risk estimate for high selenium and colon cancer, without taking folate status into
consideration, was similar to results of several other studies using pre- or peri-diagnostic
serum23;29;30 and toenails24;51 (OR=0.8). No other epidemiologic studies, to our knowledge,
have reported an interaction between selenium and folate in colon cancer risk. Many studies
of selenium and colon cancer did not discuss results regarding a potential interaction between
selenium and other dietary variables. Likewise, many studies of folate and colon cancer did
not report a possible interaction with selenium, perhaps because of the challenges of assessing
selenium intake through self-report dietary instruments.
The effect modification of selenium by folate in our study is interesting because most
epidemiologic studies report an inverse association between folate and colon cancer risk.52–
54 According to Lamprecht et al., there are three main mechanisms by which low folate might
increase the risk of colon cancer: changes in normal DNA-methylation process, imbalance of
steady state level of DNA precursors, and alterations in chromosomes and chromatin.55 Recent
in vivo and in vitro evidence, however, suggest that the relationship between folate and colon
cancer may be more complicated; it is hypothesized that folate is a dual modulator. In normal
epithelial cells, folate deficiency causes chromosomal and genomic instability, uracil
misincorporation, impaired DNA repair, increased mutations, and induces DNA strand breaks.
However, in preneoplastic or neoplastic colorectal epithelial cells, folate deficiency prevents
effective DNA synthesis, and as a result, inhibits tumor growth and progression.53;54;56–58
There is limited information about how selenium and folate interact and new information about
timing of folate consumption (before or after the neoplastic process has begun) has made this
relationship more challenging to decipher. These nutrients might interact biologically or work
independently to produce a reduced risk of colon cancer. Both are reported to improve DNA
repair mechanisms16;59, play a role in DNA methylation11;53, and support immune
function60.
Selenium and folate are both involved in DNA methylation: selenium as a methyl consumer
and folate as a methyl donor.61 Deficiency of both selenium and folate results in global DNA
hypomethylation and increased cancer susceptibility. Davis and Uthis sought to elucidate the
relationship between selenium and folate with regard to DNA methylation and found that
selenium and folate in rats had opposite effects on homocysteine concentrations.12 They also
reported that selenium modulated the detrimental effects of folate deficiency (elevated
homocysteine levels) by shunting the accumulation of homocysteine through the
transsulfuration pathway”.11;12 This inter-relationship, however, does not explain how
adequate/high levels of both nutrients might jointly reduce cancer risk.
Adequate intake of folate and selenium are reported to support a Th1 cytokine-mediated
immune response, thus, enhanced immune function is another possible mechanism by which
selenium and folate might jointly reduce the risk of colon cancer. 60 Genetic variation could
also be key to understanding a potential synergistic association between these two nutrients.
Future research on the interaction of these two nutrients is warranted.
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The third aim of our study was to evaluate possible misclassification of selenium exposure due
to stage at diagnosis, recent weight loss, and time from diagnosis to serum selenium measure.
This was done by performing analyses restricted to groups least likely to be influenced by these
biases. We did not find evidence of misclassification by any of these three characteristics.
To our knowledge, only two small studies (n<150) have investigated selenium status in relation
to colorectal cancer stage.22;35 A decrease in selenium with more advanced disease might
suggest that circulating selenium levels change in response to disease, indicating that selenium
is more likely to be a disease marker than a risk factor. Dworkin et al. found that selenium was
lower in advanced stage cancers in comparison to controls.35 Fernandez-Banares found a dose-
response relation between selenium and stage in those less than 60 years of age.22
Unfortunately, neither of these studies reported risk estimates. Our modeled risk estimates by
stage at diagnosis, indicated that high selenium, in conjunction with high folate, was associated
with decreased risk of all stages of colon cancer. Weight loss has only been quantitatively
addressed in one previous study32 and time from diagnosis to selenium measurement has not
been evaluated in previous studies.
There are several advantages to our study. First, the NCCCS had an adequate range of selenium
levels to detect a difference between high and low selenium and we used cut points established
in the NPC Trial to assess the impact of selenium levels analogous to that achieved using a 200
mcg selenium supplement. Second, the relatively large sample afforded the opportunity to
study nutrient interactions, risk estimates by stage, and evaluate several potential biases. Third,
in the evaluation of the bias by time from diagnosis to blood draw, the wide range of time
periods (1–18 months) permitted the investigation of this potential bias in selenium and cancer
associations from case-control studies. Fourth, detailed information was available on various
diet and lifestyle factors that are important potential confounders of the association between
selenium and colon cancer. Fifth, sera from cases and controls were handled in the same manner
and assayed at the same lab. Finally, selection bias was not likely because characteristics of
the total study population were very similar to the study subpopulation with measured selenium.
Certain limitations should also be acknowledged. Folate food fortification occurred during data
collection and the extent to which this secular change may have affected the dietary intakes of
study participants is uncertain. Furthermore, we analyzed multiple dietary risk factors for colon
cancer as potential effect measure modifiers, increasing the likelihood of a subgroup finding.
Although we did not find evidence of bias by weight change, time from diagnosis to blood
draw, or stage at diagnosis, there might be other concerns with regards to the use of post-
diagnostic serum. There has also been debate over the most appropriate measure of selenium
status (toenails, serum/plasma, erythrocytes); however, a recent article suggests that both
toenail and plasma selenium levels similarly reflect selenium intake.62 Finally, as in all case-
control studies, recall bias could be a problem if case status influenced report of diet or lifestyle
factors. Selenium was not prone to recall bias because it was measured in serum, however,
folate intake was self-reported and, thus, subject to this form of bias.
In conclusion, high levels of serum selenium and reported folate jointly produced a
substantially reduced risk of local and regional/distant colon cancers. Our findings suggest that
it is important to take folate status into account when evaluating the relation between selenium
and colon cancer in future studies. Stage at diagnosis, weight loss, and time from diagnosis to
blood draw were not sources of bias in our study.
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